Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

S. Kristian Hill, John A. Sweeney, Robert M. Hamer, Richard S E Keefe, Diana O. Perkins, Hogbin Gu, Joseph P. Mcevoy, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes.

Original languageEnglish (US)
Pages (from-to)209-221
Number of pages13
JournalJournal of the International Neuropsychological Society
Volume14
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Cognition
Antipsychotic Agents
Schizophrenia
Clinical Trials
Efficiency
Aptitude
Therapeutics
olanzapine
Risperidone
Psychotic Disorders
Statistical Factor Analysis

Keywords

  • Antipsychotics
  • BACS
  • CATIE
  • Clinical trials methodology
  • Cognition
  • Neuropsychology
  • Schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. / Hill, S. Kristian; Sweeney, John A.; Hamer, Robert M.; Keefe, Richard S E; Perkins, Diana O.; Gu, Hogbin; Mcevoy, Joseph P.; Lieberman, Jeffrey A.

In: Journal of the International Neuropsychological Society, Vol. 14, No. 2, 03.2008, p. 209-221.

Research output: Contribution to journalArticle

Hill, S. Kristian ; Sweeney, John A. ; Hamer, Robert M. ; Keefe, Richard S E ; Perkins, Diana O. ; Gu, Hogbin ; Mcevoy, Joseph P. ; Lieberman, Jeffrey A. / Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. In: Journal of the International Neuropsychological Society. 2008 ; Vol. 14, No. 2. pp. 209-221.
@article{898804aaf4ae4a6d883d8cba4d5b13b6,
title = "Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia",
abstract = "Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes.",
keywords = "Antipsychotics, BACS, CATIE, Clinical trials methodology, Cognition, Neuropsychology, Schizophrenia",
author = "Hill, {S. Kristian} and Sweeney, {John A.} and Hamer, {Robert M.} and Keefe, {Richard S E} and Perkins, {Diana O.} and Hogbin Gu and Mcevoy, {Joseph P.} and Lieberman, {Jeffrey A.}",
year = "2008",
month = "3",
doi = "10.1017/S1355617708080570",
language = "English (US)",
volume = "14",
pages = "209--221",
journal = "Journal of the International Neuropsychological Society",
issn = "1355-6177",
publisher = "Cambridge University Press",
number = "2",

}

TY - JOUR

T1 - Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

AU - Hill, S. Kristian

AU - Sweeney, John A.

AU - Hamer, Robert M.

AU - Keefe, Richard S E

AU - Perkins, Diana O.

AU - Gu, Hogbin

AU - Mcevoy, Joseph P.

AU - Lieberman, Jeffrey A.

PY - 2008/3

Y1 - 2008/3

N2 - Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes.

AB - Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Participants were primarily first episode schizophrenia patients who completed baseline (n = 367) and 12-week (n = 219) assessments with the BACS (Brief Assessment of Cognition in Schizophrenia) and CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) neuropsychological batteries in a clinical trial comparing olanzapine, quetiapine, and risperidone. Exploratory factor analysis revealed that performance on both batteries was characterized by a single factor of generalized cognitive deficit for both baseline performance and cognitive change after treatment. Both batteries estimated similar levels of change following treatment, although the BACS battery required half the administration time. Because a unitary factor characterized baseline cognitive abilities in early psychosis as well as cognitive change after treatment with atypical antipsychotic medications, short batteries such as the BACS may efficiently provide sufficient assessment of procognitive treatment effects with antipsychotic medications. Assessment of cognitive effects of adjunctive therapies targeting specific cognitive domains or impairments may require more extensive testing of the domains targeted to maximize sensitivity for detecting specific predicted cognitive outcomes.

KW - Antipsychotics

KW - BACS

KW - CATIE

KW - Clinical trials methodology

KW - Cognition

KW - Neuropsychology

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=39549107542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549107542&partnerID=8YFLogxK

U2 - 10.1017/S1355617708080570

DO - 10.1017/S1355617708080570

M3 - Article

VL - 14

SP - 209

EP - 221

JO - Journal of the International Neuropsychological Society

JF - Journal of the International Neuropsychological Society

SN - 1355-6177

IS - 2

ER -